Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Jan 2018
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 28 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2013 New source identified and integrated (ECOG2810: Robert H. Lurie Comprehensive Cancer Center, Northwestern University).
- 29 Nov 2012 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.